Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions

International Journal of Audiology

Volumn 50, Issue 2, 2011, Pages 112-122

  Al Malky, Ghada ^a   Suri, Ranjan ^b   Dawson, Sally J ^a   Sirimanna, Tony ^b   Kemp, David ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Aminoglycoside antibiotics; Cochleotoxicity; Cystic fi brosis paediatric population; Distortion product otoacoustic emissions; Hearing assessment; High frequency audiometry; Ototoxicity

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ADOLESCENT; ARTICLE; BACTERIAL PNEUMONIA; CHEMICALLY INDUCED DISORDER; CHILD; CYSTIC FIBROSIS; EVOKED RESPONSE AUDIOMETRY; FEMALE; HEARING LOSS; HUMAN; MALE; PURE TONE AUDIOMETRY;

ADOLESCENT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; AUDIOMETRY, EVOKED RESPONSE; AUDIOMETRY, PURE-TONE; CHILD; CYSTIC FIBROSIS; FEMALE; HEARING LOSS; HUMANS; MALE; PNEUMONIA, BACTERIAL;

EID: 79251634704     PISSN: 14992027     EISSN: 17088186     Source Type: Journal    
DOI: 10.3109/14992027.2010.524253     Document Type: Article

References (65)

1. American Speech-Language-Hearing Association. 1994. American Speech-Language-Hearing Association: Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 36 (suppl. 12), 11-19.
2. Aran J.M. 1995. Current perspectives on inner ear toxicity. Otolaryngol Head Neck Surg, 112, 1, 133-144.
3. Arnold D.J., Lonsbury-Martin B.L. & Martin G.K. 1999. High-frequency hearing influences lower-frequency distortion-product otoacoustic emissions. Arch Otolaryngol Head Neck Surg, 125, 2, 215-222.
4. Bailey T.C., Little J.R., Littenberg B., Reichley R.M. & Dunagan W.C. 1997. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis, 24, 5, 786-795.
5. Barclay M.L., Begg E.J., Chambers S.T., Thornley P.E., Pattemore P.K. et al. 1996. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother, 37, 6, 1155-1164.
6. Barza M., Ioannidis J.P., Cappelleri J.C. & Lau J. 1996. Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ, 312, 7027, 338-345. (Pubitemid 26049400)
7. Begg E.J. & Barclay M.L. 1995. Aminoglycosides: 50 years on. Br J Clin Pharmacology, 39, 6, 597-603.
8. Brummett I.E. 1980. Drug-induced ototoxicity. Drugs, 19, 6, 412-428.
9. BASE. 1992. Recommended procedure for tympanometry. British Society of Audiology Br J Audiol, 26, 4, 255-257.
10. Campbell K. 2003. Ototoxicity: Understanding oxidative mechanisms. J Am Acad Audiol, 14, 3, 121-123.
11. Campbell K.C., Meech R.P., Klemens J.J., Gerberi M.T., Dyrstad S.S. et al. 2007. Prevention of noise- and drug-induced hearing loss with D-methionine. Hear Res, 226, 1-2, 92-103.
12. Cheng A.G., Johnston P.R., Luz J., Uluer A., Fligor B. et al. 2009. Sensorineural hearing loss in patients with cystic fibrosis. Otolaryngol Head Neck Surg. 141, 1, 86-90.
13. Chen Y., Huang W.G., Zha D.J., Qiu J.H., Wang J.L. et al. 2007. Aspirin attenuates gentamicin ototoxicity: From the laboratory to the clinic. Hear Res, 226, 1-2, 78-182.
14. Cone L.A. 1982. A survey of prospective, controlled clinical trials of gentamicin, tobramycin, amikacin, and netilmicin. Clin Ther, 5, 2, 155-162.
15. Conrad D.J., Stenbit A.E., Zettner E.M., Wick I., Eckhardt C. et al. 2008. Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population. Pharmacogenet Genomics, 8, 12, 1095-1102.
16. Conway S.P., Miller M.G., Ramsden C. & Littlewood J.M. 1985. Intensive treatment of pseudomonas chest infection in cystic fibrosis: A comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin. Acta Paediatr Scand, 74, 1, 107-113.
17. Crifo S., Antonelli M., Gagliardi M., Lucarelli N. & Marcolini P. 1980. Ototoxicity of aminoglucoside antibiotics in long-term treatment for cystic fibrosis. Int J Pediatr Otorhinolaryngol, 2, 3, 251-253.
18. Fausti S.A., Larson V.D., Noffsinger D., Wilson R., Phillips D.S. et al. 1994. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear, 15, 3, 232-239.
19. Fausti S.A., Rappaport B.Z., Schechter M.A., Frey R.H., Ward T.T. et al. 1984. Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: Selected case studies. Am J Otolaryngol, 5, 3, 177-182.
20. Fetoni A.R., Sergi B., Ferraresi A., Paludetti G. & Troiani D. 2004. alpha-Tocopherol protective effects on gentamicin ototoxicity: An experimental study. Int J Audiol, 43, 3, 166-171.
21. Fischel-Ghodsian N., Prezant T.R., Chaltraw W.E., Wendt K.A., Nelson R. et al. 1997. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am J Otolaryngol, 18, 3, 173-178. (Pubitemid 27215295)
22. Forge A. & Schacht J. 2000. Aminoglycoside antibiotics. Audiol Neurootol, 5, 1, 3-22.
23. Fox K.E., Brummett R.E., Brown R. & Himes D. 1980. A comparative study of the ototoxicity of gentamicin and gentamicin C1. Arch Otolaryngol, 106, 1, 44-49.
24. Frank T. 2001. High-frequency (8 to 16 kHz) reference thresholds and intrasubject threshold variability relative to ototoxicity criteria using a Sennheiser HDA 200 earphone. Ear Hear, 22, 2, 161-168.
25. Friend P.A. 1986. Pulmonary infection in cystic fibrosis. J Infect, 13, 1, 55-72.
26. Gallo-Teran J., Arellano B., Morales-Angulo C., Modamio-Hoybjor S., Moreno-Pelayo M.A. et al. 2004. Prevalence of the A1555G mutation in the mitochondrial DNA in patients with cochlear or vestibular damage due to aminoglycoside-induced ototoxicity. Acta Otorrinolaringol Esp, 55, 5, 212-217.
27. Govaerts P.J., Claes J., van de Heyning P.H., Jorens P.G., Marquet J. & De Broe M.E. 1990. Aminoglycoside-induced ototoxicity, Toxicol Lett, 52, 3, 227-251.
28. Groh D., Pelanova J., Jilek M., Popelar J., Kabelka Z. et al. 2006. Changes in otoacoustic emissions and high-frequency hearing thresholds in children and adolescents. Hear Res, 212, 1-2, 90-98.
29. Guan M.X., Fischel-Ghodsian N. & Attardi G. 2000. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet, 9, 12, 1787-1793.
30. Gurtler N., Schmuziger N., Kim Y., Mhatre A.N., Jungi M. & Lalwani A.K. 2005. Audiologic testing and molecular analysis of 12S rRNA in patients receiving aminoglycosides, Laryngoscope, 115, 4, 640-644.
31. Haughton P.M. 1995. Audiometer calibration: applying the earphone to the coupler, Br J Audiol, 29, 3, 188-191.
32. Hobbie S.N., Akshay S., Kalapala S.K., Bruell C.M., Shcherbakov D. et al. 2008. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc Natl Acad Sci USA, 105, 52, 20888-20893.
33. Jacob L.C., Aguiar F.P., Tomiasi A.A., Tschoeke S N. & Bitencourt R.F. 2006. Auditory monitoring in ototoxicity, Braz J Otorhinolaryngol, 72, 6, 836-844.
34. Kahlmeter G. & Dahlager J.I. 1984. Aminoglycoside toxicity: A review of clinical studies published between 1975 and 1982. J Antimicrob Chemother, 13, Suppl. A, 9-22.
35. Katbamna B., Homnick D.N. & Marks J.H. 1998. Contralateral suppression of distortion product otoacoustic emissions in children with cystic fibrosis: Effects of tobramycin. J Am Acad Audiol, 9, 3, 172-178.
36. Knight K.R., Kraemer D.F. & Neuwelt E.A. 2005. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol, 23, 34, 8588-8596.
37. Knight K.R., Kraemer D.F., Winter C. & Neuwelt E.A. 2007. Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol, 25, 10, 1190-1195.
38. Lightfoot G.R. 2000. Audiometer calibration: interpreting and applying the standards. Br J Audiol, 34, 5, 311-316.
39. Littman T.A., Magruder A. & Strother D.R. 1998. Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: Pediatric case study. J Am Acad Audiol, 9, 4, 257-262.
40. Lonsbury-Martin B.L. & Martin G.K. 2001. Evoked otoacoustic emissions as objective screeners for ototoxicity. Sem Hear, 22, 377-391.
41. Lutman M.E. & Davis A.C. 1994, The distribution of hearing threshold levels in the general population aged 18-30 years. Audiology, 33, 6, 327-350.
42. Mulheran M. & Degg C. 1997. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. Br J Audiol, 31, 1, 5-9.
43. Mulheran M., Degg C., Burr S., Morgan D.W. & Stableforth D.E. 2001. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrobial Agents & Chemotherapy, 45, 9, 2502-2509.
44. Mulherin D., Fahy J., Grant W., Keogan M., Kavanagh B. & FitzGerald M. 1991. Aminoglycoside induced ototoxicity in patients with cystic fibrosis. Irish Journal of Medical Science, 160, 6, 173-175.
45. Pedersen S.S., Jensen T., Osterhammel D. & Osterhammel P. 1987. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrobial Agents and Chemotherapy, 31, 4, 594-599.
46. Prezant T.R., Chaltraw W.E. Jr. & Fischel-Ghodsian N. 1996. Identification of an overexpressed yeast gene which prevents aminoglycoside toxicity. Microbiology, 142, 12, 3407-3414.
47. Rasmussen A.N., Osterhammel P.A., Lund S.P., Kristiansen G.B. & Andersen S. 2005. A system for measuring distortion product otoacoustic emissions at ultra-sonic frequencies in rodents. Int J Audiol, 44, 4, 237-243.
48. Reavis K.M., Phillips D.S., Fausti S.A., Gordon J.S., Helt W.J. et al. 2008. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss. Ear Hear, 29, 6, 875-893.
49. Ress B.D., Sridhar K.S., Balkany T.J., Waxman G.M., Stagner B.B. et al. 1999, Effects of cis-platinum chemotherapy on otoacoustic emissions: The development of an objective screening protocol. Third place: Resident Clinical Science Award 1998, Otolaryngol Head Neck Surg, 121, 6, 693-701.
50. Riethmueller J., Ballmann M., Schroeter T.W., Franke P., von Butler R. et al and German Multicenter Study Group. 2009. Tobramycin once-vs. thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection, 37, 5, 424-431.
51. Sataloff J., Wagner S. & Menduke H. 1964. Kanamycin ototoxicity in healthy men. Arch Otolaryngol, 80, 413-417.
52. Selimoglu E. 2007. Aminoglycoside-induced ototoxicity. Curr Pharm Des, 13, 1, 119-126.
53. Sha S.H., Qiu J.H. & Schacht J. 2006. Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med, 354, 17, 1856-1857.
54. Sha S.H. & Schacht J. 2000. Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is apotential protectant. Hear Res, 142, 1-2, 34-40.
55. Sinswat P., Wu W.J., Sha S.H. & Schacht J. 2000. Protection from ototoxicity of intraperitoneal gentamicin in guinea pig. Kidney Int, 58, 6, 2525-2532.
56. Smith P.A. & Foster J.R. 1997. Audiometer calibration: Two neglected areas. Br J Audiol, 31, 5, 359-364.
57. Smyth A.R. & Tan K.H. 2006. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.[update of Cochrane Database Syst Rev. 2000; (4):CD002009; PMID: 11034740]. [Review] [29 refs]. Cochrane Database of Systematic Reviews, 3, CD002009.
58. Stavroulaki P., Vossinakis I.C., Dinopoulou D., Doudounakis S., Adamopoulos G. et al. 2002, Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis. Arch Otolaryngol Head Neck Surg, 128, 2, 150-155.
59. Szaff M., Hoiby N. & Flensborg E.W. 1983. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand, 72, 5, 651-657. (Pubitemid 13048784)
60. Tan K.H., Mulheran M., Knox A.J. & Smyth A.R. 2003. Aminoglycoside prescribing and surveillance in cystic fibrosis. [Review] [47 refs]. American Journal of Respiratory & Critical Care Medicine, 167, 6, 819-823.
61. Van Meter D.J., Corriveau M., Ahern J.W. & Lahiri T. 2009. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatric Pulmonology, 44, 4, 325-329.
62. Voldöich L. 1965. The kinetics of streptomycin, kanamycin and neomycin in the inner ear. Acta Oto-Laryngologica, 60, 1, 243-248.
63. Waterson J.A. and Halmagyi G.M. 1998. Unilateral vestibulotoxicity due to systemic gentamicin therapy. Acta Otolaryngol (Stockh), 118, 474-478.
64. Wood P.J., Ioannides-Demos L.L., Li S.C., Williams T.J., Hickey B. et al. 1996. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis", Thorax, 51, 4, 369-373.
65. Wright G.D., Berghuis A.M. & Mobashery S. 1998. Aminoglycoside antibiotics. structures, functions, and resistance. Adv Exp Med Biol, 456, 27-69.